Oncolytic virus-antibody combinations enhance immune-mediated killing of osteosarcoma
A major barrier to effective immunotherapy in osteosarcoma (OS) is the highly immunosuppressive tumour microenvironment (TME), which limits immune recognition and elimination of tumour cells. We evaluated a panel of oncolytic herpes simplex viruses (oHSVs) for their direct oncolytic activity, immune-modulatory properties and capacity to counteract OS-associated immunosuppression using…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.